Agenda Details | ASGCT Annual Meeting

Detailed Program

Tuesday, May 16 2023
01:30 PM – 03:15 PM PT

Risks of Autologous ex vivo Gene Therapy and Considerations for Improvement

The success of ex vivo gene therapy has relied on chemotherapeutic conditioning agents to “make space” in the hematopoietic stem cell niche and support engraftment of new gene-modified cells. However, using these agents carries risks of malignancy. This session will discuss alternative conditioning methods, risks of clonal hematopoiesis arising from gene therapy, and a discussion on therapeutic chimerism levels.

Session Details

01:30 PM – 03:15 PM - Petree Hall C

Co-Chair

Melissa A. Bonner, PhD. Bluebird bio, Cambridge, MA

01:30 PM – 03:15 PM - Petree Hall C

Co-Chair

Stefano Rivella, PhD. Children's Hospital of Philadelphia, Philadelphia, PA

01:31 PM – 01:55 PM - Petree Hall C

Alternative Conditioning Strategies and New Antibody Based Regimens

Megan D.. Hoban, PhD. Magenta Therapeutics, Cambridge, MA

01:55 PM – 02:20 PM - Petree Hall C

Risk of Clonal Hematopoiesis from Autologous Gene Therapies (and Baseline)

Coleman Lindsley, MD, PhD. Dana Farber Cancer Institute, Boston, MA

02:20 PM – 02:45 PM - Petree Hall C

Therapeutic Chimerism Levels in SCD (haplo)

Francis J. Pierciey, Jr.. bluebird bio, MA

02:45 PM – 03:10 PM - Petree Hall C

Ab Conditioning for Primary Immunodeficiencies

Judith Shizuru, PhD, MD. Stanford University School of Medicine, Stanford, CA